BACKGROUND: Preclinical studies demonstrated antiproliferative synergy of 1,25-D3 (calcitriol) with cisplatin. The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic non-small-cell lung cancer. METHODS: Patients were ≥18 years, PS 0-1 with normal organ function. In the phase I portion, patients received escalating doses of 1,25-D3 intravenously every 21 days prior to docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) using standard 3 + 3 design, targeting dose-limiting toxicity (DLT) rate <33 %. Dose levels of 1,25-D3 were 30, 45, 60, and 80 mcg/m(2). A two-stage design was employed for phase II portion. We correlated CYP24A1 tagSNPs with clinical outcome and 1,25-D3 pharmacokinetics (PK). RESULTS: 34 patients were enrolled. At 80 mcg/m(2), 2/4 patients had DLTs of grade 4 neutropenia. Hypercalcemia was not observed. The RP2D of 1,25-D3 was 60 mcg/m(2). Among 20 evaluable phase II patients, there were 2 confirmed, 4 unconfirmed partial responses (PR), and 9 stable disease (SD). Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4). CYP24A1 SNP rs3787554 (C > T) correlated with disease progression (P = 0.03) and CYP24A1 SNP rs2762939 (C > G) trended toward PR/SD (P = 0.08). There was no association between 1,25-D3 PK and CYP24A1 SNPs. CONCLUSIONS: The RP2D of 1,25-D3 with docetaxel and cisplatin was 60 mcg/m(2) every 21 days. Pre-specified endpoint of 50 % confirmed RR was not met in the phase II study. Functional SNPs in CYP24A1 may inform future studies individualizing 1,25-D3.
BACKGROUND: Preclinical studies demonstrated antiproliferative synergy of 1,25-D3 (calcitriol) with cisplatin. The goals of this phase I/II study were to determine the recommended phase II dose (RP2D) of 1,25-D3 with cisplatin and docetaxel and its efficacy in metastatic non-small-cell lung cancer. METHODS:Patients were ≥18 years, PS 0-1 with normal organ function. In the phase I portion, patients received escalating doses of 1,25-D3 intravenously every 21 days prior to docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) using standard 3 + 3 design, targeting dose-limiting toxicity (DLT) rate <33 %. Dose levels of 1,25-D3 were 30, 45, 60, and 80 mcg/m(2). A two-stage design was employed for phase II portion. We correlated CYP24A1 tagSNPs with clinical outcome and 1,25-D3 pharmacokinetics (PK). RESULTS: 34 patients were enrolled. At 80 mcg/m(2), 2/4 patients had DLTs of grade 4 neutropenia. Hypercalcemia was not observed. The RP2D of 1,25-D3 was 60 mcg/m(2). Among 20 evaluable phase II patients, there were 2 confirmed, 4 unconfirmed partial responses (PR), and 9 stable disease (SD). Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4). CYP24A1 SNP rs3787554 (C > T) correlated with disease progression (P = 0.03) and CYP24A1 SNP rs2762939 (C > G) trended toward PR/SD (P = 0.08). There was no association between 1,25-D3 PK and CYP24A1 SNPs. CONCLUSIONS: The RP2D of 1,25-D3 with docetaxel and cisplatin was 60 mcg/m(2) every 21 days. Pre-specified endpoint of 50 % confirmed RR was not met in the phase II study. Functional SNPs in CYP24A1 may inform future studies individualizing 1,25-D3.
Authors: R St-Arnaud; A Arabian; R Travers; F Barletta; M Raval-Pandya; K Chapin; J Depovere; C Mathieu; S Christakos; M B Demay; F H Glorieux Journal: Endocrinology Date: 2000-07 Impact factor: 4.736
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Guoan Chen; So Hee Kim; Amanda N King; Lili Zhao; Robert U Simpson; Paul J Christensen; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Lin Lin; Dean E Brenner; David G Beer; Nithya Ramnath Journal: Clin Cancer Res Date: 2010-12-17 Impact factor: 12.531
Authors: Haiqing Shen; Lawrence F Bielak; Jane F Ferguson; Elizabeth A Streeten; Laura M Yerges-Armstrong; Jie Liu; Wendy Post; Jeffery R O'Connell; James E Hixson; Sharon L R Kardia; Yan V Sun; Min A Jhun; Xuexia Wang; Nehal N Mehta; Mingyao Li; Daniel L Koller; Hakan Hakonarson; Brendan J Keating; Daniel J Rader; Alan R Shuldiner; Patricia A Peyser; Muredach P Reilly; Braxton D Mitchell Journal: Arterioscler Thromb Vasc Biol Date: 2010-09-16 Impact factor: 8.311
Authors: Frank Fossella; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panagiotis Fidias; Michael Millward; Chandra P Belani Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Josephia R Muindi; Yibing Peng; Douglas M Potter; Pamela A Hershberger; Jil S Tauch; Mary Jo Capozzoli; Merrill J Egorin; Candace S Johnson; Donald L Trump Journal: Clin Pharmacol Ther Date: 2002-12 Impact factor: 6.875
Authors: Pamela A Hershberger; Terence F McGuire; Wei-Dong Yu; Eleanor G Zuhowski; Jan H M Schellens; Merrill J Egorin; Donald L Trump; Candace S Johnson Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261
Authors: Josephia R Muindi; John W Wilson; Ying Peng; Mary Jo Capozolli; Candace S Johnson; Donald L Trump Journal: J Clin Pharmacol Date: 2003-08 Impact factor: 3.126
Authors: Holly P Quach; Qi J Yang; Edwin C Chow; Donald E Mager; Stacie Y Hoi; K Sandy Pang Journal: Br J Pharmacol Date: 2015-05-15 Impact factor: 8.739
Authors: Alissa R Verone-Boyle; Suzanne Shoemaker; Kristopher Attwood; Carl D Morrison; Andrew J Makowski; Sebastiano Battaglia; Pamela A Hershberger Journal: Oncotarget Date: 2016-01-05